Submissions received during the consultation period on the PMPRB Price Review Approach During the Interim Period following publication of Amendments to the Patented Medicines Regulations
- AbbVie Corporation (PDF 527 KB)
- Amgen Canada Inc. (PDF 494 KB)
- Astellas Pharma Canada, Inc. (PDF 542 KB)
- AstraZeneca Canada Inc. (PDF 179 KB)
- Association québécoise des pharmaciens propriétaires (PDF 454 KB)[available in French only]
- Bayer Inc. (PDF 165 KB)
- BC Ministry of Health (PDF 207 KB)
- BIOTECanada (PDF 256 KB)
- Boehringer Ingelheim (Canada) Ltd (PDF 157 KB)
- Bristol Myers Squibb Canada Co. (PDF 152 KB)
- Canadian Generic Pharmaceutical Association (CGPA) (PDF 116 KB)
- Canadian Organization for Rare Disorders (CORD) (PDF 169 KB)
- CONECTed (PDF 52 KB)
- Cystic Fibrosis Canada (PDF 365 KB)
- Danish Life Sciences Forum (PDF 112 KB)
- Eli Lilly Canada Inc. (PDF 225 KB)
- Elvium Life Sciences (PDF 113 KB)
- Fédération des chambres de commerce du Québec (PDF 352 KB)[available in French only]
- Gastrointestinal Society (PDF 201 KB)
- Gilead Sciences Canada, Inc. (PDF 87 KB)
- GlaxoSmithKline Inc. (PDF 452 KB)
- Government of Newfoundland and Labrador (PDF 43 KB)
- Hoffmann – La Roche Limited (PDF 213 KB)
- Innovative Medicines Canada (PDF 142 KB)
- Janssen Inc. (PDF 195 KB)
- Joint Submission from Distributor/Pharmacy Associations (ABCPQ, AQDP, CAPDM, CPA, NPAC) (PDF 213 KB)
- LEO Pharma Canada (PDF 152 KB)
- Life Sciences Ontario (PDF 175 KB)
- McKesson Canada (PDF 147 KB)
- Merck Canada Inc. (PDF 271 KB)
- Novartis Pharmaceuticals Canada Inc. (PDF 649 KB)
- PDCI Market Access (PDF 193 KB)
- Pfizer Canada (PDF 589 KB)
- RAREi - The Canadian Forum for Rare Disease Innovators (PDF 260 KB)
- Save Your Skin Foundation (PDF 50 KB)
- Sunovion Pharmaceuticals Canada Inc. (PDF 171 KB)
- Takeda Canada Inc (PDF 135 KB)
Page details
- Date modified: